CervoMed Inc. (NASDAQ: CRVO)
$19.73
+1.7200 ( +9.55% ) 120.2K
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Market Data
Open
$19.73
Previous close
$18.01
Volume
120.2K
Market cap
$163.18M
Day range
$17.62 - $20.35
52 week range
$4.28 - $26.38
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | May 15, 2024 |
10-q | Quarterly Reports | 63 | May 14, 2024 |
def | Proxies and info statements | 9 | Apr 29, 2024 |
8-k | 8K-related | 14 | Apr 23, 2024 |
8-k | 8K-related | 16 | Apr 05, 2024 |
8-k | 8K-related | 14 | Apr 04, 2024 |
10-k | Annual reports | 88 | Mar 29, 2024 |
8-k | 8K-related | 19 | Mar 28, 2024 |
8-k | 8K-related | 14 | Mar 18, 2024 |
8-k | 8K-related | 17 | Mar 05, 2024 |